Literature DB >> 7852153

Thymoma in dogs: 23 cases (1980-1991).

S W Atwater1, B E Powers, R D Park, R C Straw, G K Ogilvie, S J Withrow.   

Abstract

Medical records of 23 dogs in which thymoma was diagnosed between Jan 1, 1980 and Dec 31, 1991 were reviewed. All thymomas were located in the cranial mediastinum. Eleven dogs had megaesophagus, and myasthenia gravis was confirmed in 7 of these 11. One dog developed clinical signs of myasthenia gravis after removal of the thymoma. Concurrent, nonthymic neoplasms were found in 5 dogs, and 2 had hypercalcemia. Three dogs developed third-degree atrioventricular heart block, 1 of which had generalized myositis involving the cardiac muscle. None of the dogs had evidence of distant metastasis. Histologically, the predominant tumor types were differentiated epithelial type (9/23) and lymphocyte-rich type (6/23). Clear cells (large cells with nonstaining cytoplasm) comprised > or = 50% of the cell population in tumors from 5 dogs. Mast cells were detected histologically in 85% of the thymomas evaluated. Sixteen dogs were treated, and in 15 of these, surgery was the primary means of treatment. Six of the 9 dogs with megaesophagus that underwent surgery died or were euthanized within 1 week of diagnosis; whereas only 1 of the 4 dogs without megaesophagus that underwent surgery died within 1 week of diagnosis. Two dogs underwent surgery and received adjuvant chemotherapy. One dog died of complications associated with chemotherapy. One dog was treated with chemotherapy alone and survived 14 months. Seven dogs did not undergo treatment; 4 of these were euthanatized immediately after the mass was first discovered.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1994        PMID: 7852153

Source DB:  PubMed          Journal:  J Am Vet Med Assoc        ISSN: 0003-1488            Impact factor:   1.936


  9 in total

Review 1.  A review of immunologic diseases of the dog.

Authors:  N C Pedersen
Journal:  Vet Immunol Immunopathol       Date:  1999-08-02       Impact factor: 2.046

Review 2.  Thymoma and multiple malignancies: a case of five synchronous neoplasms and literature review.

Authors:  James S Welsh; Sarah A Thurman; Steven P Howard
Journal:  Clin Med Res       Date:  2003-07

3.  Coincidence of thymoma and breast cancer and in a 56-year-old female patient.

Authors:  Evangelia Athanasiou; Electra Michalopoulou-Manoloutsiou; Mattheos Bobos; Dimitris I Hatzibougias; Paul Zarogoulidis; Nikolos Katsikogiannis; Eirini Sarika; Ilias Karapantzos; Nikolaos Barbetakis; Dimitrios Paliouras; Fotis Chatzinikolaou; Charalampos Charalampidis; Ioanna Kougioumtzi; Alexandros Kolettas; Andreas Bakas; Keraso Tzelepi; Efstratios Kalaitzis; Kosmas Tsakiridis
Journal:  Ann Transl Med       Date:  2016-11

4.  Serum parathyroid hormone-related protein concentration in a dog with a thymoma and persistent hypercalcemia.

Authors:  P Foley; D Shaw; C Runyon; S McConkey; B Ikede
Journal:  Can Vet J       Date:  2000-11       Impact factor: 1.008

5.  Focal myasthenia gravis in a dog.

Authors:  A A Webb; S M Taylor; L McPhee
Journal:  Can Vet J       Date:  1997-08       Impact factor: 1.008

6.  Mixed Thymoma in a Young Cynomolgus Monkey (Macaca fascicularis).

Authors:  Yuri Kotani; Junko Sato; Yumi Wako; Minoru Tsuchitani
Journal:  J Toxicol Pathol       Date:  2010-10-05       Impact factor: 1.628

7.  Risk Factors and Outcomes in Cats with Acquired Myasthenia Gravis (2001-2012).

Authors:  D W Hague; H D Humphries; M A Mitchell; G D Shelton
Journal:  J Vet Intern Med       Date:  2015-08-26       Impact factor: 3.333

8.  Concurrent renal amyloidosis and thymoma resulting in a fatal ventricular thrombus in a dog.

Authors:  Jennifer M Loewen; Rachel E Cianciolo; Liwen Zhang; Michael Yaeger; Jessica L Ward; Jodi D Smith; Dana N LeVine
Journal:  J Vet Intern Med       Date:  2018-02-27       Impact factor: 3.333

9.  Orthostatic hypotension secondary to a suspected thymoma in a dog: a case report.

Authors:  Jeremy Hansford; Natalia Henao-Guerrero
Journal:  BMC Vet Res       Date:  2020-10-13       Impact factor: 2.741

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.